Anticholinergics: How These Common Medications Affect Memory and Cause Dry Mouth

Many older adults take anticholinergic medications without realizing they could be slowly harming their brain. These drugs - found in common treatments for overactive bladder, allergies, depression, and Parkinson’s - block acetylcholine, a key chemical for memory and focus. What seems like a simple fix for one problem might be quietly setting the stage for another: memory loss, confusion, and even faster brain shrinkage.

What Are Anticholinergics and Why Are They So Common?

Anticholinergics are a class of drugs that stop acetylcholine from doing its job in the brain and body. Acetylcholine helps with learning, attention, muscle control, and saliva production. When you block it, you reduce symptoms like bladder spasms, excessive sweating, or tremors. But you also turn off important signals in the brain.

These drugs aren’t rare. About 1 in 3 older adults in the U.S. are taking at least one medication with anticholinergic effects. Common ones include:

• Oxybutynin (for overactive bladder)
• Diphenhydramine (Benadryl, for allergies and sleep)
• Amitriptyline (for depression and nerve pain)
• Trihexyphenidyl (for Parkinson’s)

They work. That’s why doctors still prescribe them. But the trade-off isn’t always clear to patients. And the longer you take them, the more your brain pays the price.

The Brain Changes You Can’t See

It’s not just feeling foggy. Brain scans show real, measurable damage. People taking high-anticholinergic drugs (rated 2 or 3 on the Anticholinergic Cognitive Burden scale) lose brain volume faster than those who don’t take them. One study of 451 older adults found they had:

• 0.5% to 1.2% more brain shrinkage per year
• 8% to 14% less glucose use in the hippocampus - the memory center
• 10% to 15% larger ventricles (fluid-filled spaces in the brain, which grow when brain tissue shrinks)

These changes aren’t just numbers on a scan. They show up in daily life. Users of high-burden anticholinergics performed 23% to 32% worse on memory tests and 18% to 27% worse on tasks requiring planning or focus. And it gets worse with time. Each extra point on the ACB scale added 0.3% more brain loss per year.

Dr. Shannon Risacher, who led one of the key studies, said: “These findings help explain how these drugs might push the brain toward dementia.” In her study, 63% of long-term users developed mild cognitive impairment or Alzheimer’s within 10 years - compared to 38% of non-users.

Dry Mouth Isn’t Just Uncomfortable - It’s a Warning Sign

If you’re constantly thirsty, chewing gum all day, or struggling to swallow food, your dry mouth isn’t just annoying. It’s a direct sign the drug is working - and working too hard.

Anticholinergics block acetylcholine in the salivary glands, reducing saliva by up to 70%. This isn’t a rare side effect. Eighty-two percent of users on Drugs.com report severe dry mouth. Some describe needing 2-3 liters of water daily just to speak or eat. Others say their tongue feels glued to the roof of their mouth.

But dry mouth does more than make life unpleasant. It increases the risk of:

• Tooth decay and gum disease
• Difficulty swallowing (which can lead to choking or pneumonia)
• Bad breath and mouth infections

It’s also a red flag. If you’re feeling this dry, your brain is likely being affected too - because the same mechanism causing dry mouth is also blocking signals in your memory centers.

Not All Anticholinergics Are Created Equal

Here’s the good news: you don’t have to take a high-risk drug if there’s a safer option.

Drugs are rated on the Anticholinergic Cognitive Burden (ACB) scale from 0 to 3:

• ACB 3 (High Risk): Scopolamine, diphenhydramine, oxybutynin
• ACB 2 (Medium Risk): Amitriptyline, tolterodine
• ACB 1 (Low Risk): Glycopyrrolate, trospium, darifenacin, tiotropium
• ACB 0 (No Risk): Mirabegron, solifenacin (low ACB), beta-3 agonists

For overactive bladder - one of the most common uses - oxybutynin (ACB 2-3) causes 28% more cognitive decline than tolterodine (ACB 1-2). But there’s an even better choice: mirabegron. It works just as well for bladder control, has zero anticholinergic effects, and doesn’t cause dry mouth or brain fog. The problem? It costs $350 a month. Generic oxybutynin? $15.

Many doctors still reach for the cheap option. But the long-term cost to your brain may be far higher.

When Stopping Isn’t Safe - And What to Do Instead

Some people need anticholinergics. If you have Parkinson’s and stop your medication suddenly, your tremors and stiffness can explode. Abruptly quitting amitriptyline can trigger severe withdrawal.

But that doesn’t mean you’re stuck. The goal isn’t always to quit - it’s to reduce risk.

Experts recommend:

• Using the lowest dose possible
• Taking it for the shortest time needed
• Switching to lower-ACB alternatives when available
• Monitoring cognition every 6 months with the MoCA test

For dry mouth, try sugar-free gum (boosts saliva by 30-40%), prescription saliva substitutes like Xerolube, or pilocarpine - a drug that actually stimulates saliva production. A 2018 NEJM study showed pilocarpine increased salivary flow by 50-70%.

What’s Changing in 2026 - And What You Should Know

The tide is turning. In 2022, the FDA required stronger warning labels on 12 high-risk anticholinergics. The UK’s NICE guidelines now recommend deprescribing these drugs in 68% of long-term users over 65. Medicare prescriptions for high-ACB drugs have dropped 22% since 2015.

Newer drugs are being designed to avoid the brain. Trospium chloride XR (Sanctura XR) has 70% less brain penetration than oxybutynin. Karuna Therapeutics’ xanomeline - being tested for Alzheimer’s psychosis - causes 40% less dry mouth than older antipsychotics.

And AI tools are stepping in. Systems like MedAware now flag risky prescriptions before they’re written. One study predicts these tools could prevent 200,000-300,000 dementia cases per year in the U.S. by cutting inappropriate prescriptions by half.

What to Do Now

If you or someone you care about is on an anticholinergic, ask these questions:

1. What’s the ACB score of this medication?
2. Is there a non-anticholinergic alternative? (Like mirabegron for bladder issues)
3. Can we try a lower dose or switch to a low-ACB version?
4. Have we checked cognitive function in the last 6 months?
5. Are we managing dry mouth - not just ignoring it?

Don’t stop medication on your own. But do ask. Your brain is worth the conversation.